TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice by Pihlgren, Maria et al.
doi:10.1182/blood-2012-02-413831
Prepublished online November 8, 2012;
2013 121: 85-94
 
 
 
 
Thomas M. Kündig, Andreas Muhs and Pål Johansen
Lucia Buccarello, Valérie Gafner, Nathalie Chuard, Pedro Reis, Kasia Piorkowska, Andrea Pfeifer,
Fettelschoss, David T. Hickman, María Pilar López-Deber, Dorin Mlaki Ndao, Marija Vukicevic, Anna 
Maria Pihlgren, Alberto B. Silva, Rime Madani, Valérie Giriens, Ying Waeckerle-Men, Antonia
 
independent isotype switch in mice−liposomes enables T cell
TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide
 http://bloodjournal.hematologylibrary.org/content/121/1/85.full.html
Updated information and services can be found at:
 (4911 articles)Immunobiology   
Articles on similar topics can be found in the following Blood collections
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
 http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
 Copyright 2011 by The American Society of Hematology; all rights reserved.
Washington DC 20036.
by the American Society of Hematology, 2021 L St, NW, Suite 900, 
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly
 
 
 
 
 only.
For personal use at UNIVERSITAETSSPITAL on January 4, 2013. bloodjournal.hematologylibrary.orgFrom 
Regular Article
IMMUNOBIOLOGY
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Key Points
• Peptide assemblies on MPLA-
containing liposomes induce
IgG responses independent of
T cells, CD40L, CD28, CD14,
and MyD88.
• Direct stimulation of B cells
through TLR4 and TRIF is re-
quired for T cell–independent
IgG responses.
Immunoglobulin class switching from IgM to IgG in response to peptides is generally
T cell–dependent and vaccination in T cell–deficient individuals is inefficient. We show
that a vaccine consisting of a dense array of peptides on liposomes induced peptide-
specific IgG responses totally independent of T-cell help. Independency was confirmed
in mice lacking T cells and in mice deficient for MHC class II, CD40L, and CD28. The IgG
titers were high, long-lived, and comparable with titers obtained in wild-type animals,
and the antibody response was associated with germinal center formation, expression
of activation-induced cytidine deaminase, and affinity maturation. The T cell–
independent (TI) IgG response was strictly dependent on ligation of TLR4 receptors on
B cells, and concomitant TLR4 and cognate B-cell receptor stimulation was required on
a single-cell level. Surprisingly, the IgG class switch was mediated by TIR-domain-
containing adapter inducing interferon- (TRIF), but not by MyD88. This study demon-
strates that peptides can induce TI isotype switching when antigen and TLR ligand are
assembled and appropriately presented directly to B lymphocytes. A TI vaccine could enable efficient prophylactic and therapeutic
vaccination of patients with T-cell deficiencies and find application in diseases where induction of T-cell responses contraindicates
vaccination, for example, in Alzheimer disease. (Blood. 2013;121(1):85-94)
Introduction
Most peptide and protein antigens require T-cell help for B-cell
activation and antibody production,1 while polysaccharides and
lipopolysaccharide (LPS) can stimulate antibody responses without
T help.2 In both T cell–independent (TI) and –dependent (TD)
antibody responses, cognate antigens bind their B-cell receptor
(BCR). TD antigens are internalized, processed, and presented in
the context of MHC class II molecules to antigen-specific T-helper
cells.3 The activated T cell then facilitates B-cell responses and
immunoglobulin isotype switching via costimulatory molecules,
adhesive antigens, and cytokines. TI antigens typically stimulate
transient IgM antibody production with little or no IgG, IgA, or IgE
production. TI type 1 (TI-1) antigens are polyclonal B-cell activators
such as LPS whereas TI type 2 (TI-2) antigens consist of repetitive
biochemical structures, such as polysaccharides or glycoproteins.4
Liposomes are submicron vesicles of phospholipids and allow
integration of compounds within and on the lipid bilayer. Antigens
can be packed on the surface to resemble TI-2 antigens; in nature,
repetitive arrangement of a single protein or peptide on cells or
microorganisms does not typically occur. In the present study, a
peptide was palmitoylated and mixed with phospholipids and
monophosphoryl lipid A (MPLA) to allow formation of liposomes
with densely arranged peptides on the outer surface. The palmitoy-
lated human -amyloid (A, aa1-15) peptide adopts an aggregated
-sheet conformation on liposomes.5 While previous reports have
suggested that nonreplicating protein vaccines do not enable
TI isotype switching,6,7 the present study in mice demonstrates that
switch is feasible with a correct structural assembly of antigen and
adjuvant. This result could pave the way for vaccination of patients
with T-cell deficiencies or elderly, or when T-cell involvement is
associated with immunopathology or autoimmunity, for example,
encephalitis in Alzheimer disease.
Methods
Mice
Mice deficient for CD14 (B6.129S-Cd14tm1Frm/J), CD28 (B6.129S2-
Cd28tm1Mak/J), CD40L (B6.129S2-Cd40lgtm1Imx/J), TCR  and 
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(B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J), MHC class II (B6.129S2-
Ciitatm1Ccum/J), MyD88 (B6.129P2(SJL)-Myd88tm1Defr/J), TIR-domain-
containing adapter inducing interferon- (TRIF; C57BL/6J-Ticam1Lps2/J),
MT (B6.129S2-Ighmtm1Cgn/J) as well as nude mice (B6.Cg-Foxn1nu/J)
were purchased from The Jackson Laboratory. Wild-type (WT) C57BL/6
mice were purchased from Charles River. All treatments were approved by
the Local Committee for Animal Use and were carried out in accordance to
state and federal regulations.
Preparation of liposomes
Liposomes containing the palmitoylated human A antigen aa1-15
[H-K(Palm)-K-(Palm)-DAEFRHDSGYEVHHQ-K(Palm)-K(Palm)-OH],
short PalmA1-15, (Bachem) were prepared from dimyristoyl phosphatidyl
choline (Lipoid), dimyristoyl phosphatidyl glycerol (Lipoid), cholesterol
(Solvay), and MPLA (Avanti Polar Lipids) at molar ratios 9:1:7:0.06.5,8 The
liposomes were sterilized by filtration and endotoxin free. Each dose
(200 L) contained 78 g of PalmA1-15 and 12 g of MPLA.
Preparation of OVA-Alum vaccines
Ovalbumin (OVA; Sigma-Aldrich) in PBS (1 mg/mL), was mixed with
aluminum hydroxide (Alum; Alhydrogel, Brenntag Biosector) to obtain a
final concentration of 5 mg/mL Alum. The OVA/Alum solution was mixed
with CpG (CpG ODN 1668, phosphorothioate-modified as indicated by
asterisks in the 5-3 sequence: T*CC ATG ACG TTC CTG A*C*G *T*T;
Microsynth). Each vaccine dose of 200 L contained 100 g of OVA,
1000 g of Alum, and 60 g of CpG.
Immunizations
Mice were immunized subcutaneously (s.c.) with 200 L of liposomes at
various intervals. Blood serum samples prepared before and at various time
points after immunization were frozen at 20°C for later antibody analysis
by ELISA. For analysis of T-cell responses, mice were immunized s.c. with
A1-15 liposomes or with OVA, Alum, and CpG on days 0 and 10. On day
15, spleens were harvested for cell-proliferation assay and ELISPOT
analysis.
Germinal center analysis by immunohistochemistry and flow
cytometry
Wild-type, athymic and CD28/, CD40L/, or TCR/ mice were
immunized with liposomes containing A1-15 and MPLA as described in
“Immunizations,” and spleens were harvested for the analysis of germinal
centers (GCs) and activation-induced cytidine deaminase (AID) expression.
Half of the spleen was snap-frozen for immunohistology, while half the
spleen was freshly homogenized for analysis by flow cytometry. The frozen
sections were stained with peanut agglutinin PNA, anti–GL-7, or anti-AID
(eBioscience). GL-7– and B220-positive B cells in erythrocyte-freed spleno-
cytes were analyzed by flow cytometry (eBioscience). Acquisition was
done with FACSCanto (BD Biosciences) and analysis with FlowJo
8.5.2 (TreeStar).
Quantification of OVA- and A-specific cytokine producing
T cells by ELISPOT
Cytokine production of OVA- or A-specific splenocytes was assessed by
ELISPOT according to the manufacturers’ instructions (Mabtech) after
incubation of cells with 2M OVA, 2M A1-42, or 5 g/mL Concanava-
lin A (GE Healthcare) at 37°C and 5% CO2 for 48 hours. The plates were
then washed and incubated with biotinylated anti–mouse IFN- or
IL-4 monoclonal antibodies and developed using streptavidin-alkaline
phosphatase (AP), substrate BCIP-NBT.
Measurement of A-specific and OVA-specific antibody
responses
A1-42–specific and OVA-specific IgG and IgM antibodies were deter-
mined by ELISA. Plates were coated with 10 g/mL A1-42 (Bachem) or
30 g/mL OVA overnight at 4°C and blocked with 1% BSA. Serial
dilutions of serum (1/100 to 1/12 600) were analyzed with AP-conjugated
anti-mouse IgG total antibody (Jackson ImmunoResearch Laboratories),
HRP-conjugated IgM antibody (BD Bioscience/BD Pharmingen), or
subclass-specific antibodies (IgG1-AP, IgG2a/c-biotin, IgG3-biotin;
BD Pharmingen) or IgG2b-AP (Zymed Laboratories). For IgG2a/c,9 and
IgG3 Streptavidin-HRP was used. The ELISAs were developed with
AP (pNPP) or HRP (ABTS) substrates. The results for IgG are expressed
with reference to the antibody 6E10 (Covance) and as optical density (OD) at a
nonsaturated plasma dilution for IgM, IgG1, IgG2a/c, IgG2b, and IgG3.
CDR sequencing
The antibody variable regions of 3 antibodies obtained from mice immu-
nized with A liposomes were sequenced and compared with germline
murine immunoglobulin sequences in the NCBI database. Differences
exactly at the VDJ or V to J joining points were not considered as sequence
changes attributable to affinity maturation.
Biacore assay
Surface plasmon resonance (SPR) binding measurements were carried out
on a Biacore T100 instrument (GE Healthcare) at 25°C using PBS as
running buffer. Acetylated human A antigen aa1-15 [H-K(Ac)-K-(Ac)-
DAEFRHDSGYEVHHQ-K(Ac)-K(Ac)-OH], short Acetyl1-15, (PolyPep-
tides) was solubilized in acetate buffer pH 4.0 at 4 mg/mL and immobiliza-
tion on a Serie S sensor chip CM5 (GE Healthcare) using amine coupling,
giving a final immobilization level of 1239 RUs. Sera from wild-type and
nude mice immunized with PBS or A-peptide liposomes sampled at day 7 and
day 56 were assessed. Four serial dilutions between 50- and 400-fold were
assayed using running buffer at a flow rate of 50L/min for 120 seconds. After
injection was finished, the surfaces were washed immediately with running
buffer for 240 seconds. Surface regeneration was performed by injecting one
time 2.5L of 10mM Glycine-HCl pH 1.7.
Binding to the negative control surface (underivatized flow cell 1) was
subtracted from each sample curve and maximal response unit was
measured at 120 seconds postinjection. Normalized dissociation was calcu-
lated as a ratio of late to early binding responses over a dissociation phase of
360 seconds.10 For each serum, the normalized dissociation obtained at
days 7 and 56 were compared from dilutions giving binding curves with
similar maximal response unit.
ELISA for avidity measurements
Avidity measurements of serum antibodies were performed as described.11
The ELISA was optimized so that the amount of antibody binding to the
coated peptide represented  10% of antibodies in the liquid phase. Each
serum was adjusted to an optimal concentration (OD of 3.0) and was
incubated with different concentrations of A1-42 for 2 hours at 37°C. The
serum was transferred to the coated plates and the ELISA performed as
described in “Measurement of OVA- and A-specific antibody responses.”
The IC50 values were calculated by “log (inhibitor) vs response” fitting
using GraphPad Prism software.
Cryo-TEM measurements
Liposomes (4-5 L) were applied to an EM grid with a holey carbon film.
The grid was blotted and frozen, and the image acquisition was made at
170°C in a Philips CM12 electron microscopy (FEI Electron Optics)
equipped with a Gatan 626 cryospecimen holder and a magnification of
	22 000. Digital images were recorded with a Gatan MultiScan charge-
coupled device (CCD) camera and processed with Gatan Digital Micro-
graph software.
Adoptive transfer
Single-cell suspensions of splenocytes were prepared from TLR4-deficient,
TRIF-deficient, or WT mice after red blood cell lysis. The cells were
washed and resuspended in PBS, and 100 million cells were injected
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intravenously into each MT mouse, which were immunized as described
in “Immunizations” with A1-15 and MPLA liposomes 18 hours later.
Statistical analysis
All statistical analyses were performed using Prism Version 5 (GraphPad
Software). Data were analyzed by 1-way or 2-way ANOVA followed by
Tukey posthoc analysis for multiple comparisons or by 2-sided Kruskal-
Wallis nonparametric tests (when n  10). The significance level was
set at 0.05.
Results
A-peptide liposomes stimulate rapid A-specific IgG antibody
responses with no evidence of T-cell activation
The A1-15 peptide is anchored in the unilaminar bilayer through
4 palmitoyl chains, and the adjuvant MPLA is integrated into the
lipid bilayer through 6 fatty acid chains (Figure 1A-B). Immuniza-
tion of wild-type (WT) C57BL/6 mice with A1-15 liposomes
triggered strong anti-A IgG responses (
 100 000 ng/mL) within
7 days, and repeated injections on days 14 and 28 did not boost the
titers (Figure 1C). IgG2b was the dominant subclass, but high titers
of IgG3 and IgG2a/c were also measured (Figure 1D). Both the
rapid appearance of IgG antibodies and the stimulation of IgG3
production suggested a TI antibody production.12
Full-length A peptide (A1-42) contains T-cell epitopes, while
truncated A1-15 used here lacks known T-cell epitopes.13 Conse-
quently, no detectable antigen-specific secretion of IFN- (Figure
1E) or IL-4 (Figure 1F) was observed in splenocytes restimulated
in vitro with A1-42. In contrast, significant T-cell responses were
observed in mice immunized with the TD antigen OVA (Figure
1G-H). Antigen-specific proliferation was also observed in cells from
OVA but not from A1-15–immunized mice (data not shown).
Antibody responses induced by A-peptide liposomes are
T-cell independent
WT mice depleted of CD4 T cells and immunized with A1-15
liposomes produced a robust anti-A IgG response, which did not
differ from nondepleted mice (Figure 2A). For comparison, CD4
T-cell depletion reduced OVA-specific IgG responses in mice immu-
nized with OVA (Figure 2B). The CD4 T-cell depletion (
 98%) was
confirmed by flow cytometric analysis (data not shown), but to rule out a
potential contribution by residual CD4 T cells, the same experiment
was performed in MHC II–deficient mice, which lack mature CD4
T cells. Again, A1-15 liposomes induced anti-A IgG responses
comparable with those observed in WT mice (Figure 2C).
A strong and persistent anti-A IgG response in athymic nude
mice and in TCR-deficient mice lacking both  and  T cells
further verified a TI-antibody response (Figure 2D). The anti-A
IgM titers were also comparable in WT, nude and TCR-deficient
mice (Figure 2E). The predominance of the IgG2b subclass and
TI-associated IgG3 in all 3 mice strains (Figure 2F-H) further
supporting that class switching can occur in the absence of T cells.
Peptide-specific TI IgG responses do not require APC-mediated
costimulation or antigen presentation
Although T cells were not required for the observed antibody
response, costimulation of B cells may be provided by antigen-
presenting cells (APCs). CD80/CD28, CD86/CD28, and CD40/
Figure 1. Immunization with A-peptide liposomes induces a rapid anti-A IgG antibody response but no T-cell activation. (A) Schematic representation of A-peptide
liposomes. A1-15 is attached to liposomes by palmitoyl chains coupled to the side chain of 4 lysines. The adjuvant MPLA integrates into the liposomes through fatty acid
chains. (B) Cryoelectron microscopy of A-peptide liposomes. The liposomes consist of unilamellar bilayers. Scale bar shows 50 nm. (C) Anti-A IgG antibodies in the plasma
of C57BL/6 mice immunized with A-peptide liposomes or PBS. Mice were injected s.c. at days 0, 14, and 28 (as indicated by arrows) and bled before and 7, 21, 35, and
56 days after the first immunization. Results are expressed as mean  SD (n  9 per group). The data are representative of more than 10 independent experiments.
(D) Anti-A IgG subclasses in the plasma of C57BL/6 mice receiving A-peptide liposomes or PBS at day 35. Results are expressed as OD values at a dilution of 1/400 and
shows mean  SD (n  9 per group). The data are representative of more than 5 independent experiments. (E-H) IFN- and IL-4 production of splenocytes from immunized
mice restimulated with (E-F) A1-42 or (G-H) OVA in vitro. C57BL/6 mice were injected s.c. at days 0 and 10 with A-peptide liposomes or OVA/CpG/Alum and analyzed for
cytokine production 15 days after the first immunization. Results are expressed for 10 individual mice per group with the mean indicated by a line. NS indicates not significant.
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CD40L interactions have been reported important for GC forma-
tion and class switching.14-16 We found that immunization with
A1-15 liposomes induced strong anti-A IgM and IgG responses
both in the CD28- and CD40L-deficient mice (Figure 3A-B).
Again, predominance of IgG2b and TI-associated IgG3 similar to
that observed in WT mice (Figure 3C-E).
To evaluate whether the observed TI antibody responses
were dependent on the peptide amino acid sequence, a liposomal
vaccine containing a Tau peptide was prepared (data not shown).
Circular dichroism spectroscopy showed a typical -sheet/
-strand conformation of the peptide when integrated into
liposomes, similar to that of the A1-15, and Thioflavin-T
binding indicated that the Tau peptide was aggregated on the
surface of the liposomes. Tau-peptide liposomes induced antigen-
specific IgG responses in both WT and nude mice with similar
IgG subclass distribution, which further suggests T-cell indepen-
dency and underline the importance of the structural arrange-
ment of antigen and adjuvant.
A liposomes stimulates germinal center and somatic
hypermutation with affinity maturation
Immunization of WT mice with A1-15 liposomes caused forma-
tion of GCs in both lymph node (not shown) and spleens (Figure
4A) by day 7 as shown histologically by PNA stainings in the
follicles. The GCs were large and observed in almost every follicle.
This was accompanied by increased expression of the GC marker
GL-7 expression both histologically and as measured by flow
cytometry (Figure 4B) as well as expression of activation-induced
(cytidine) deaminase (AID), which mutates the Ig locus, thereby
altering binding affinity for antigen (Figure 4A). Surprisingly, GC
formation as well as the GL-7 and AID expression was also found
after immunization of CD28-, CD40L-, and TCR-deficient mice
(Figure 4A-B). In contrast, GC formation and GL-7/AID staining
were not observed in naive mice. While evident that CD40L or
CD28 were not required for GC formation and AID expression
after immunization with A1-15 liposomes, the magnitude and
quality of such formation were slightly different. WT mice showed
PNA-staining GCs in almost each follicle and the GCs were
typically more distinct with sharp marginal zones. Deficient mice
generally had lower number of GCs, and these were less distinct
than those observed in WT mice. Especially in TCR-deficient mice,
the GC formation was slower, being stronger on day 13 than day
7 postimmunization (data not shown).
The CDR regions of the heavy and light chains of 3 monoclonal
antibodies generated after A1-15 liposome vaccination were
sequenced. Two antibodies each had one mutation in the heavy
Figure 2. A-peptide liposomes induces a rapid,
robust, and persistent antibody response indepen-
dent of CD4 T cells, / T cells, and / T cells.
(A) Anti-A or (B) anti-OVA IgG antibodies in the plasma
of WT mice or CD4-depleted WT mice immunized with
A-peptide liposomes or OVA/Alum, respectively; deple-
tion was done by weekly i.p. injections of 100 g (opti-
mized in house, data not shown) anti-CD4 antibody
(clone YTS191.1; AbD Serotec) starting 3 days before
immunization, and verified by flow cytometry on blood
sampled on days 0, 7, 14, and 21. Results are expressed
as mean  SD (n  8 per group). Arrows indicate time of
immunization (d0); ***P  .001. (C) Anti-A IgG antibod-
ies in the plasma of MHC II/ and WT mice receiving
A-peptide liposomes at day 0 and 7. Results are
expressed as mean  SD (n  6 per group). (D) Anti-A
IgG antibodies in the sera of WT, nude, and TCR/ mice
receiving A-peptide liposomes (as indicated by arrows).
Results are expressed as mean  SD (n  6 per group).
(E) Analysis of anti-A IgM in the sera of WT, nude, and
TCR/ mice from day 7. Results are expressed as mean
OD values at a dilution of 1/100  SD (n  6 per group).
(F-H) Analysis of anti-A IgG subclasses in the sera of
WT, nude, and TCR/ mice receiving A-peptide lipo-
somes. Analysis of IgG subclasses were done on sera
prepared from blood on day 28. Results are expressed as
mean  SD OD values at a dilution of 1/400 (n  6 per
group).
88 PIHLGREN et al BLOOD, 3 JANUARY 2013  VOLUME 121, NUMBER 1 only.
For personal use at UNIVERSITAETSSPITAL on January 4, 2013. bloodjournal.hematologylibrary.orgFrom 
chains, suggesting that these antibodies have undergone affinity
maturation (data not shown). To confirm this, we evaluated the
avidity of the antibodies in sera from immunized WT and nude
mice by SPR (Biacore) and competitive ELISA. By SPR, the
dissociation of antibodies was slower in sera collected 56 days after
immunization compared with sera from day 7 (Figure 4C-D). The
relative dissociations were 0.59 (day 7) and 0.83 (day 56) for WT,
or 0.50 (day 7) and 0.68 (day 56) for nude mice. Hence, the average
avidity of the antibodies has increased over time in both WT and
T cell–deficient nude mice. By competitive ELISA, the average
avidity of the antibodies was also increased on day 56 compared
with day 7 in both WT and nude mice (Figure 4E).
TLR4 and TRIF activation are required for TI anti-A IgG
responses stimulated by A-peptide liposomes
We assessed whether the repetitive structure of the antigen was
sufficient for B-cell activation or whether a second signal was
needed. While the liposomes containing both A1-15 and MPLA
stimulated strong TI anti-A IgG responses, A1-15 liposomes
lacking MPLA did not trigger measurable anti-A IgG (Figure 5A)
or IgM (Figure 5B); MPLA liposomes lacking A1-15 did not
induce anti-A IgG (data not shown). This clearly indicates the
need for both antigen and MPLA stimulation.
MPLA may bind to either CD14 or the TLR4, both receptors for
LPS. Antibody responses in CD14-deficient mice were similar to
those measured in WT mice (Figure 5C). In TLR4-deficient mice,
the anti-A IgG (Figure 5C) and IgM (Figure 5D) responses were
completely abrogated. The IgG subclass distribution in WT and
CD14-deficient mice was comparable (Figure 5E).
TLR4 may signal through the adapter proteins MyD88 and/or
TRIF. CD14-independent signaling by TLR4 has been shown to be
dependent on MyD88 whereas CD14-dependent signaling acti-
vates both MyD88 and TRIF.17,18 Surprisingly, experiments in mice
lacking either MyD88 or TRIF indicated that the antibody response
was independent on MyD88, but significantly (P  .001) depen-
dent on the activation of TRIF (Figure 5F).
TLR4 and TRIF activation in B lymphocytes is needed to induce
a TI IgG response by A1-15 liposomes
To determine whether antigen and TLR ligand activated the same
cell, we injected mice with a mixture of 2 liposomal preparations,
one containing the antigen A1-15 and one containing only MPLA.
This mixture significantly induced (P  .001) lower anti-A IgG
responses than the vaccine containing adjuvant and antigen on the
same particles (Figure 6A), demonstrating that the antigen and the
adjuvant should be in close proximity for induction of a TI IgG
response. The data further suggest that the TLR4 signaling takes
place directly on the B cells and not through mediation by APCs or
other bystander cells. To verify the latter, mice specifically lacking
TLR4 on B lymphocytes were used. TLR4-deficient or WT spleno-
cytes were transferred into B cell–deficient MT mice, which were
then immunized with A1-15 liposomes with MPLA (Figure 6B).
While transfer of WT B cells expectedly enabled stimulation of
anti-A IgG responses in MT mice, no response was observed in
MT mice that received TLR4-deficient B cells (Figure 6C). Thus,
direct activation of TLR4 on B lymphocytes was critical for
induction of A-specific TI IgG responses. Similar experiments
were done by transferring TRIF-deficient B cells into B cell–
Figure 3. A-peptide liposomes induce IgG responses independent of CD40L and CD28. (A) Anti-A IgG antibodies in the sera of WT, CD40L/, and CD28/ mice
receiving A-peptide liposomes as indicated by arrows. Results are expressed as mean  SD (n  6 per group). (B) Analysis of anti-A IgM and in the sera of WT, CD40L/,
and CD28/ mice from day 7. Results are expressed as mean OD values at a dilution of 1/100 SD (n  6 per group). (C-E) Analysis of anti-A IgG subclasses in the sera of
WT, CD40L/, and CD28/ mice receiving A-peptide liposomes. Analysis of IgG subclasses were done on sera prepared from blood on day 28. Results are expressed as
mean OD values at a dilution of 1/400 SD (n  6 per group).
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deficient MT mice and then immunizing these with the MPLA-
containing A1-15 liposomes. The results revealed that the TRIF
dependency observed above (Figure 5F) was associated with TRIF
signaling directly on B cells because the antigen-specific IgG
responses observed after transfer of WT B cells were abrogated in
MT that received TRIF-deficient cells (Figure 6C).
Discussion
The display of multiple copies of molecules on the surface of cells
and microorganisms can induce antibody production without the
requirement of T-helper cells when 10-20 or more B-cell receptors
are stimulated simultaneously.19-21 Such semicrystalline arrays of
antigens displayed on virus-like particles have been exploited to
increase immunogenicity of antigens and to enable thymus-
independent (TI) stimulation of B cells.6 However, in the absence
of T help, antibody responses stimulated by nonreplicating protein
antigens are characterized by short-lived IgM and no immunoglobu-
lin class switch to IgG, IgA, or IgE.6 Similarly, antigen-specific
TI IgG responses are detected in mice infected with live polyoma
virus, but not in mice immunized with synthetic polyoma-like
particles,7 suggesting that live and replicating organisms provide
costimulatory signals crucial for the isotype switching. To our
knowledge, the present study is the first to show TI IgG responses
to a protein antigen. With a liposomal array of densely packed
peptide and TLR4 ligand, long-lived IgG antibody responses were
induced in several T cell–deficient mouse strains including athymic
nude and TCR-deficient mice and in mice deficient in CD40L and
CD28 signaling, both molecules which previously have been
considered critical for the isotype switch and GC formation after
immunization with protein-based antigens. Our data also suggest
that the TI GC formation was associated with AID expression and
affinity maturation. Although the degree of affinity maturation is
difficult to estimate, the functionality of the antibodies induced by
A-peptide liposomes has been demonstrated previously by a
decrease of A species in the brain of immunized animals and a
direct correlation of the antibody titers and improved cognition in
an Alzheimer disease mouse model.8 The fact that the generated
antibodies are neutralizing strongly suggest affinity maturation.
One can also speculate that the speed of antibody production is also
paralleled by very fast affinity maturation. That is, the affinity of
the A antibody is high already by day 7. Similar observations have
been made for T cell–dependent B-cell responses induced by live
vesicular stomatitis virus.22
The repetitive display of peptide was not alone sufficient to
induce antibody responses, but required the presence of a TLR
ligand, here, MPLA. MPLA is a detoxified derivative of lipid A,
derived from LPS of Gram-negative bacteria and has recently been
Figure 4. TI germinal center formation, AID expression, and affinity maturation after immunization with A-peptide liposomes. (A) WT C57BL/6, CD28/, CD40L/,
and TCR/ mice (n  5) were immunized with MPLA-containing A1-15 liposomes, and on day 7, spleens were analyzed for germinal center formation by histologic staining
with (left panel) PNA, or antibodies against (middle panel) GL-7 or (right panel) AID. (B) GL-7 expression on B220 B cells was also analyzed by flow cytometry after dumping of
splenocytes staining positive for IgM, IgD, CD4, CD8, Gr-1, CD11b, and CD11c. Analysis by (C-D) SPR/Biacore and (E) competitive ELISA of average avidity of antibodies in
day 7 and day 56 sera from WT and nude mice immunized with A-peptide liposomes.
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approved for human use in cervical cancer, hepatitis, and influenza
vaccines.23 MPLA mediates immune responses through activation
of the TLR4/CD14/MD-2 coreceptor.24 In our study, stimulation of
TRL4 with MPLA was necessary for the induction of both IgM and
IgG responses, demonstrating that the TLR4 signaling is crucial for
initial B-cell activation and not only for class-switch recombina-
tion, as recently suggested.25 Whether the stimulation of antibody
responses requires the involvement of TLRs in general is currently
a matter of debate,26-28 but it has become clear that TLR signaling
can influence B-cell responses directly.29 In vitro, the direct
stimulation of TLR425 or TLR929 on B cells has been shown to
strengthen B-cell receptor signaling and immunoglobulin class
switch. The requirement for direct triggering of TLR on B lympho-
cytes was recently demonstrated for TD antigens displayed on
synthetic nanoparticles, where TLR4 and TLR7 ligands synergisti-
cally increased antigen-specific antibody responses.10 The current
study suggest that the cross-linking of B-cell receptors for the stimula-
tion of peptide-specific and thymus-independent antibody responses
must involve the commitment of TLR4 on the B cells (Figure 7).
TLR4 is the only TLR identified until now that activates 2 signaling
pathways, the MyD88-dependent and the TRIF-dependent pathways.30
MyD88 transmits signals culminating in NF-B activation and produc-
tion of inflammatory cytokines whereas TRIF activation leads to type I
interferon production. The low toxicity of MPLAcompared with LPS or
lipid A has been associated with the preferential activation of TRIF and
reduced MyD88 activation.31 A change from diphosphoryl (in LPS) to
monophosphoryl (in MPLA) enabled TRIF-biased and MyD88-
independent TLR4 signaling.32 More recently, the reduced MyD88
Figure 5. TLR4 and TRIF are required for the induction of anti-A IgG response by A-peptide liposomes. (A) Anti-A IgG and (B) IgM antibodies in the plasma of
WT mice receiving A-peptide liposomes (26 g of PalmA1-15) with or without 30 g of MPLA (as indicated by arrows). IgG results are expressed as mean  SD, while IgM
results are expressed as mean OD values at a dilution of 1/100  SD (n  10 per group). The data are representative of 2 independent experiments. (C) Anti-A IgG and
(D) IgM antibodies in the plasma of WT, CD14/, and TLR4/ mice immunized s.c. with A-peptide liposomes (as indicated by arrows). IgG results are expressed as
mean  SD, while IgM results from day 7 are expressed as mean OD at a dilution of 1/100  SD (n  6 per group). (E) Analysis of anti-A IgG subclasses in the sera of
WT mice, CD14/ mice, and TLR4/ mice receiving A-peptide liposomes. Results are expressed as mean OD values at a dilution of 1/400  SD (n  6 per group).
(F) Anti-A IgG antibodies in the sera of WT mice, MyD88/ mice, and TRIF/ receiving A-peptide liposomes (as indicated by arrows). IgG results are expressed as
mean  SD (n  6 per group).
Figure 6. Triggering of TLR4 and TRIF in B lymphocytes is required for the induction of TI anti-A IgG responses. (A) Anti-A IgG antibodies in the sera of WT mice
receiving liposomes containing both MPLA (19 g of MPLA per dose) and A1-15 (94 g of PalmA1-15 per dose) or a 1:1 mixture of MPLA-containing liposomes and
A1-15–containing liposomes (as indicated by arrows). The 2 liposome formulations were mixed before injection. Results are expressed as mean SD (n 10 per group).
(B) Schematic representation of the generation of mice expressing or lacking TLR4 on B lymphocytes. Splenocytes from WT, TLR4/, or TRIF/ mice were transferred into
B cell–deficient MT mice. (C) Analysis of anti-A IgG responses in B cell–deficient MT mice receiving splenocytes from WT, TLR4/, or TRIF/ mice followed by immunization with
A-peptide liposomes. Results are expressed as meanSD (n 3 per group).
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activation of MPLA was shown to be associated with impaired
inflammasome priming and reduced caspase-1 activation and IL-1
production.33,34 Consistent with these studies, we found that the IgG
secretion after immunization with MPLA-containing liposomes was
impaired in TRIF-deficient, but not in MyD88-deficient B cells. Thus,
the low toxicity of MPLA, associated with TRIF-biased signaling and
reduced production of inflammatory cytokines, still allows for TI
activation of B lymphocytes and robust IgG responses.
MyD88-independent LPS and lipid A signaling in macrophages
have previously been shown to require CD14 expression.18 Surpris-
ingly though, the TI IgG production after immunization with
liposomes containing A1-15 peptide and MPLA did not require
TLR4 signal transduction through CD14 or MyD88. As mentioned
in the paragraph above, the TRIF bias and MyD88 independency of
MPLA compared with lipid A suggest that minor structural changes
can have major impact on downstream signaling pathways. It is
possible that these structural changes can explain the combined
CD14 and MyD88 independency of MPLA as opposed to lipid A.
The fact that CD14 is not expressed on B lymphocytes but primarily on
myelomonocytic cells35 is further proof that antigen presentation does
not take place by APCs such as DCs, macrophages, and monocytes, but
that the peptide-MPLA assembly directly stimulate B-cell responses
through ligation of B-cell receptors and TLR4.
Little is known about TLR4 signaling in B lymphocytes, and it
remains to be determined whether TLR4 signaling pathways differ
between B lymphocytes and macrophages, particularly with re-
gards to the requirement for CD14, MyD88, and TRIF and how
such differences may affect humoral responses. However, it has
been suggested that TLR signaling in B cells is not required for
induction of TI type II antibody IgG3 responses, and that such a
response depended on TLR signaling in DCs and macrophages.28
The result of the present study demonstrate the contrary: TI IgG
responses, including IgG3, strictly depended on TLR signaling in
B cells and was fully independent on such signaling in professional
APCs. By the same token, it was shown that class switching in
B cells induced through transmembrane activator and calcium
modulator and cyclophilin ligand interactor (TACI) or TLR is
MyD88 dependent.36 However, this was observed using the CpG as
TLR agonist, and the study did not investigate the possibility of
class switch recombination through other TLR signaling cascades.
Our study demonstrated that class switch and GC formation can take
place in the absence of MyD88 signals when the IgG response is TI and
that TRIF and not MyD88 mediated such signaling directly on B cells.
The expression of TLR4 in mouse and human B cells differs
and this needs to be considered for vaccination of human patients.
While some studies show that human B cells do express TLR4,37
other studies suggest that TLR4 expression increases after TLR4
triggering. Indeed, TLR4 expression and function can be elevated
in human B cells from patients with inflammatory diseases such as
type 2 diabetes, periodontal disease, and Crohn disease.38 TLR4
expression has also been shown to be increased on PBMCs of
Alzheimer disease patients.39 Reports also show that TLR4 signal-
ing may have a regulating effect on the development of neuroinflam-
mation and Alzheimer disease and activate TLR4 signaling,40 for
which reason MPLA can expected to be a promising adjuvant in
vaccines for Alzheimer disease.
As mentioned, both CD80/86 (on APCs) signaling to CD28 on
T cells and CD40L (on T cells) signaling to CD40 on B cells have
been considered crucial to providing isotype switch and mainte-
nance of GCs.41 This may be true for T cell–dependent (TD)
antigens, which do not meet a minimum requirement for CD40L,
CD28, and TI class switching. MacLennan and coworkers showed
that the CD28/CD40L restriction could be manipulated in a
transgenic animal model with an abnormally high number of
antigen-specific B cells and transgenic antigen receptors with a
uniform high affinity for the TI type II hapten antigen (NP-Ficoll)
that enabled isotype switch and formation of GCs.41 Our results
suggest that such minimal requirement can be naturally overcome.
Immunization with a dense assembly of A peptide and MPLA
allowed the delivery of sufficiently strong signals to the B-cell
receptor with a potentially autocrine potentiation of the immune
response. While previous reports have suggested that nonreplicat-
ing protein vaccines require T cells for antibody isotype switch-
ing,6,7 the present study demonstrates that a switch is feasible with a
correct assembly of antigen and adjuvant. Independent of direct
signaling or secondary bystander effects from T-helper cells, high
titers of long-lasting IgG antibodies could be produced on immuni-
zation of mice with a densely packed array of peptide and MPLA
on particles made up of phospholipids. One practical implication of
this finding is the immunotherapeutic utilization in situations where
T cells are less abundant because of disease (eg, AIDS), drug-
mediated immune suppression (eg, organ transplant recipients and
cancer patients), or where T-cell activation may cause immunopa-
thology (eg, in Alzheimer disease). Indeed, immunization against
A1-42 in mice overexpressing the amyloid precursor protein
decreased the number of plaques and improved behavior deficits,
indicating that therapeutic A vaccination may be beneficial
against Alzheimer disease.42-47 However, clinical testing of A1-42
vaccination revealed promising efficacy, but that 6% of treated
patients developed encephalitis,48,49 which was attributed to a T-cell
response against A.50
Figure 7. Schematic representation of the mechanism by which peptide
liposomes can induce TI IgG responses. The peptide antigen is presented in an
aggregated repetitive -sheet conformation which allows crosslinking of several
BCRs. Presentation of peptide antigen and TLR ligand (in this case MPLA) in close
proximity, for example on liposomes, allows costimulation of BCR and TLR4 via TRIF
on the same B lymphocyte. Activation of TRIF in B lymphocytes permits B-cell
activation and class switching to IgG. T cells, MHC-II, CD40/CD40L, CD28/CD80,
CD28/CD86, CD14, and MyD88 (all marked in gray) are not required for the induction
of TI IgG responses by peptide liposomes.
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